Ocugen Statistics
Total Valuation
Ocugen has a market cap or net worth of $399.46 million. The enterprise value is $400.90 million.
| Market Cap | 399.46M |
| Enterprise Value | 400.90M |
Important Dates
The next estimated earnings date is Friday, July 31, 2026, before market open.
| Earnings Date | Jul 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ocugen has 338.52 million shares outstanding. The number of shares has increased by 10.50% in one year.
| Current Share Class | 338.52M |
| Shares Outstanding | 338.52M |
| Shares Change (YoY) | +10.50% |
| Shares Change (QoQ) | +4.87% |
| Owned by Insiders (%) | 1.35% |
| Owned by Institutions (%) | 34.68% |
| Float | 316.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 89.46 |
| Forward PS | 155.63 |
| PB Ratio | 68.77 |
| P/TBV Ratio | 68.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 89.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.86, with a Debt / Equity ratio of 5.74.
| Current Ratio | 1.86 |
| Quick Ratio | 1.54 |
| Debt / Equity | 5.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.62 |
Financial Efficiency
Return on equity (ROE) is -660.00% and return on invested capital (ROIC) is -95.37%.
| Return on Equity (ROE) | -660.00% |
| Return on Assets (ROA) | -68.24% |
| Return on Invested Capital (ROIC) | -95.37% |
| Return on Capital Employed (ROCE) | -183.04% |
| Weighted Average Cost of Capital (WACC) | 16.09% |
| Revenue Per Employee | $38,491 |
| Profits Per Employee | -$617,871 |
| Employee Count | 116 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.43% in the last 52 weeks. The beta is 2.21, so Ocugen's price volatility has been higher than the market average.
| Beta (5Y) | 2.21 |
| 52-Week Price Change | +4.43% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 1.53 |
| Relative Strength Index (RSI) | 32.44 |
| Average Volume (20 Days) | 5,255,268 |
Short Selling Information
The latest short interest is 83.02 million, so 24.52% of the outstanding shares have been sold short.
| Short Interest | 83.02M |
| Short Previous Month | 81.05M |
| Short % of Shares Out | 24.52% |
| Short % of Float | 26.20% |
| Short Ratio (days to cover) | 10.67 |
Income Statement
In the last 12 months, Ocugen had revenue of $4.47 million and -$71.67 million in losses. Loss per share was -$0.23.
| Revenue | 4.47M |
| Gross Profit | -37.01M |
| Operating Income | -66.25M |
| Pretax Income | -71.67M |
| Net Income | -71.67M |
| EBITDA | -63.87M |
| EBIT | -66.25M |
| Loss Per Share | -$0.23 |
Balance Sheet
The company has $31.86 million in cash and $33.30 million in debt, with a net cash position of -$1.44 million or -$0.00 per share.
| Cash & Cash Equivalents | 31.86M |
| Total Debt | 33.30M |
| Net Cash | -1.44M |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 5.81M |
| Book Value Per Share | 0.02 |
| Working Capital | 17.84M |
Cash Flow
In the last 12 months, operating cash flow was -$59.40 million and capital expenditures -$175,000, giving a free cash flow of -$59.58 million.
| Operating Cash Flow | -59.40M |
| Capital Expenditures | -175,000 |
| Depreciation & Amortization | 2.38M |
| Net Borrowing | n/a |
| Free Cash Flow | -59.58M |
| FCF Per Share | -$0.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,483.85% |
| Pretax Margin | -1,605.22% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ocugen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.50% |
| Shareholder Yield | -10.50% |
| Earnings Yield | -17.94% |
| FCF Yield | -14.91% |
Analyst Forecast
The average price target for Ocugen is $11.43, which is 868.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.43 |
| Price Target Difference | 868.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 261.90% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ocugen has an Altman Z-Score of -9.25 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.25 |
| Piotroski F-Score | 2 |